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Clostridium botulinum neurotoxins (BoNTs) are the most poisonous naturally occurring
protein toxins known to mankind and are the causative agents of the severe and
potentially life-threatening disease botulism. They are also known for their application
as cosmetics and as unique bio-pharmaceuticals to treat an increasing number of
neurological and non-neurological disorders. Currently, the potency of biologically active
BoNT for therapeutic use is mainly monitored by the murine LD50-assay, an ethically
disputable test causing suffering and death of a considerable number of mice. The aim
of this study was to establish an in vitro assay as an alternative to the widely used in vivo
mouse bioassay. We report a novel BoNT detection assay using mouse embryonic stem
cell-derived neurons (mESN) cultured on multi-electrode arrays (MEAs). After 21 days in
culture, the mESN formed a neuronal network showing spontaneous bursting activity
based on functional synapses and express the necessary target proteins for BoNTs.
Treating cultures for 6 h with 16.6 pM of BoNT serotype A and incubation with 1.66 pM
BoNT/A or 33 Units/ml of Botox R© for 24 h lead to a significant reduction of both
spontaneous network bursts and average spike rate. This data suggests that mESN
cultured on MEAs pose a novel, biologically relevant model that can be used to detect
and quantify functional BoNT effects, thus accelerating BoNT research while decreasing
animal use.
Keywords: botulinum neurotoxins, BoNT, botulism, embryonic stem cell-derived neurons, neuronal network,
in vitro bioassay, multi-electrode array, MEA
Abbreviations: APV, (2R)-amino-5-phosphonovaleric acid; BoNT, botulinum neurotoxin; CNQX, 6-cyano-7-
nitroquinoxaline-2,3-dione; DAPI, 4’,6-Diamidin-2-phenylindol; EB, embryoid body; ELISA, enzyme-linked immunosorbent
assay; FRET, Förster resonance energy transfer; GABA A, G-aminobutyric acid A; GAD1, glutamate-decarboxylase 1; GFAP,
glial fibrillary acidic protein; HC, heavy chain; LC, light chain; LD50, median lethal dose; MBA, mouse bioassay; MEA,
multi-electrode array; mESC, mouse embryonic stem cell; mESN, mouse embryonic stem cell-derived neurons; PBS,
phosphate-buffered saline; SNARE, soluble N-ethyl maleimide sensitive factor attachment protein receptor; SV2, synaptic
vesicle glycoprotein 2; Syn 1, synapsin 1a/b; SNAP-25, synaptosomal-associated protein of 25 kDa; TTX, tetrodotoxin;
VGLUT 2, vesicular glutamate transporter 2.
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INTRODUCTION
The BoNTs are produced and secreted by the bacteria Clostridium
botulinum, C. butyricum, and C. baratii and are amongst the
most lethal substances known, with an estimated human lethal
dose of 0.1–2 ng/kg if applied intravenously (Arnon et al., 2001;
Simpson, 2004). Seven BoNT serotypes (A–G) and more than 40
subtypes are currently described, where BoNT/A, B, E, and F have
been directly associated with human illness causing symptoms
of botulism with four naturally occurring syndromes (Simpson,
2004; Lindstrom and Korkeala, 2006; Rusnak and Smith, 2009).
Recently, the California Department of Public Health published
data on the finding of a C. botulinum strain IBCA10-7060
that produced BoNT/B and another BoNT that could not
be neutralized by any of the provided monovalent polyclonal
botulinum antitoxins raised against BoNTs A–G (Barash and
Arnon, 2014). The novel BoNT was thereupon described as a
newly defined serotype H. However, this has been questioned
by several groups and additional studies were recommended
to confirm its identity (Johnson, 2014; Rossetto et al., 2014).
Recent published data has now shown that BoNT/H (alternatively
termed BoNT/FA) has a chimeric structure containing regions
similar to the structures of BoNT/A1, BoNT/F1, and BoNT/F5
(Kalb et al., 2015; Maslanka et al., 2016; Pellett et al., 2016).
Foodborne botulism is caused by ingestion of BoNT
contaminated food whereas wound botulism is caused by
germination of C. botulinum spores in wounds and in situ
toxin production. Infant botulism as well as the rarest form, the
adult botulism, results through ingestion of spores which can
germinate in the intestinal tract and produce BoNTs (Lindstrom
and Korkeala, 2006). Clinical symptoms occur 2–36 h after
exposure, depending on dose and route of admission and are
characterized by a generalized weakness which progresses to a
flaccid paralysis that can ultimately lead to respiratory arrest and
subsequent death due to suffocation (Bohnel and Gessler, 2005).
All BoNTs are synthesized as 150 kDa polypeptides and
processed by post-translational proteolytic cleavage to yield a
100 kDa HC and a 50 kDa LC linked by a disulfide bond. They
are further subdivided in functionally independent domains.
Neuronal cell entry of the toxin is mediated by a multi-step
process requiring fully functional BoNT holotoxins (Brunger and
Rummel, 2009). In a first step, the HC domain, located at the
C-terminal portion of the HC, mediates binding to polysialo
gangliosides (e.g., GD1a and GT1b) which are present in high
density on the presynaptic membrane, thus establishing the initial
anchorage to the neuronal membrane (Rummel, 2016). Upon
successful binding toward these polysialo gangliosides, BoNTs
bind additionally via the HC domain to different synaptic vesicle
receptors located on the presynaptic membrane. Specifically,
BoNT/A, D, E and F bind to the SV2 receptor and BoNT/B and
G bind to synaptotagmin I/II (Rummel, 2016). After binding
to both receptors, BoNTs are internalized by receptor mediated
endocytosis (Montal, 2010). Upon successful uptake, the HN
domain, located at the C-terminal portion of the HC, translocates
the LC into the neuronal cytosol where it exerts its enzymatic
activity, acting as a zinc-dependent endopeptidase (Fischer and
Montal, 2007). LC specifically targets and cleaves different
SNAREs which play crucial roles in synaptic exocytosis (Schiavo
et al., 2000; Montal, 2010). In particular, BoNT/A, C and E
cleave SNAP-25 and in addition BoNT/C also cleaves syntaxin
whereas BoNT/B, D, F, and G cleave the vesicle associated
membrane protein-1 and -2 (Binz, 2013; Rossetto et al., 2014).
Proteolysis of any of these three proteins prevents the assembly
of the conserved synaptic exocytosis complex, thus blocking
neurotransmitter release leading to the symptoms associated with
clinical botulism.
BoNT/A and to a lesser extent BoNT/B are used as
pharmaceuticals to treat a variety of neuromuscular disorders,
chronic pain and in cosmetics (Jankovic, 2004; Naumann et al.,
2008). Due to their extreme high potency, these pharmaceuticals
need to be carefully titrated to ensure clinical benefits with
minimal side effects. Furthermore, BoNT has been classified
as a category A Select Agent due to the high lethality, lack
of therapeutic options and potential misuse as a bioterrorism
weapon (Arnon et al., 2001; Bossi et al., 2006).
Currently, the standard method for BoNT detection and
quantification makes use of an in vivo mouse bioassay (MBA),
in which the test material is injected intraperitoneally or
intravenously in mice and signs of toxicity are observed until
death occurs due to respiratory arrest (Schantz and Johnson,
1990). The MBA is a sensitive and robust assay, but faces
several disadvantages: a large number of animals are required,
lab to lab variations can occur, high costs accrue and up to
4 days are necessary to yield results. The assay also inflicts
severe suffering to the mice and may lead to suffocation within
the test period, underlining the need for alternative in vitro
methods able to reduce or replace the use of live animals (Adler
et al., 2010). Many different in vitro assays have already been
established, which are capable of detecting BoNTs or BoNT
catalytic activity with an equal or higher sensitivity than the
MBA. Depending on the type of samples to be analyzed (highly
purified toxin or crude samples), different prerequisites for the
assay are necessary. For the analysis of reported botulism cases in
humans and animals, the assay must detect all serotypes in a fast
manner and has to be compatible with different environmental,
clinical, and food matrices (e.g., serum, feces). In contrast to
the pharmaceutical product, those samples require only a rough
estimate of the toxin’s catalytic activity. Established and sensitive
methods capable of detecting BoNTs in complex matrices include
immunological detection methods (e.g., direct or indirect ELISA)
or endopeptidase assays (Dorner et al., 2013). For the analysis and
potency testing of pharmaceutical preparations the assay must
determine the toxin’s catalytic activity in a highly precise manner
and has to detect all steps of BoNT action, including binding
to specific receptors, internalization into neurons, translocation
of the LC into the cytosol and proteolytic cleavage of SNARE
proteins. Duration of the assays and matrix effects are not
relevant to the testing of pharmaceutical products, since they are
composed of highly pure toxins or toxin complexes diluted in
physiological buffer containing additives and stabilizing proteins.
ELISA assays do not differentiate between holotoxin and reduced
toxin in which the HC and LC are separated and endopeptidase
assays only detect the proteolytic activity of the LCs, thus
hold several important restrictions in replacing the MBA for
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the analysis and potency testing of pharmaceutical preparations
(Pellett, 2013).
In contrast, neuronal cell-based assays provide a model which
includes all steps of cellular intoxication, including binding
to the cell surface, endocytosis, translocation of the LC into
the cytosol and enzymatic activity of the LC toward SNARE
substrates. Several cell-based assays using continuous cell lines,
primary neuron cultures or stem cell-derived neurons have
been developed over the past years exceeding the sensitivity
of the MBA thus offering an alternative method for BoNT
potency determination (Pellett, 2013). In fact, Allergan Inc.,
the distributor of Botox R©, published data for an alternative
detection assay using a continuous cell line which has been
approved by the Food and Drug Administration as a replacement
method for potency testing of pharmaceuticals (Fernandez-
Salas et al., 2012). This assay, along with others, uses SNARE
cleavage as endpoint readout for BoNT activity which can be
determined in cell lysates by Western blot or by direct/indirect
ELISA. Therefore, they depend on destructive homogenization
of tissue to allow quantification and assessment thus requiring
additional methods and further hands-on time to yield a result
(Nuss et al., 2010; Pellett et al., 2010, 2011; McNutt et al.,
2011; Whitemarsh et al., 2012). SNARE cleavage has also been
determined in live cells by quantitative immunofluorescence
using cleavage-specific antibodies enabling a potential high-
throughput method for the detection of BoNT/A (Kiris
et al., 2011). By using FRET and introducing a SNARE-
FRET construct transiently into PC12 cells, that undergoes a
change in fluorescence emission upon successful BoNT-mediated
cleavage, Dong et al. (2004) were able to detect the biological
activity of BoNT/A. An alternative endpoint readout for the
analysis of BoNT activity is the inhibition of neurotransmitter
release that can be determined by different approaches, e.g.,
pre-loading cells with radioactively labeled neurotransmitter
(Keller and Neale, 2001; Sheridan et al., 2005) or endogenous
neurotransmitter release can be directly measured by high-
performance liquid chromatography or immunoassays (Welch
et al., 2000; McNutt et al., 2011). Another approach is whole-
cell patch-clamp recordings of mESN to evaluate changes in
synaptic transmission following treatment with BoNT/A. This
synaptic function assay revealed to be more sensitive than
molecular readouts of SNARE substrate cleavage (Beske et al.,
2015).
Multi-electrode arrays represent a unique tool to investigate
network dynamics and allow a concurrent and non-invasive
recording of electrical activity from many neurons and other
cell types simultaneously. In the past, these have been widely
used to characterize the spontaneous and evoked activity of
neuronal networks (Shahaf and Marom, 2001; Tscherter et al.,
2001; Bonifazi et al., 2005; Ban et al., 2007). Of note, the effects
of neuroactive compounds on neurons cultivated on MEAs can
be easily monitored (Pancrazio et al., 2003, 2014; Johnstone et al.,
2010; McConnell et al., 2012).
In the present study, we have established a novel in vitro
method where alterations in synaptic transmission after BoNT/A
treatment are detectable in mESN grown on MEAs. We could
show for the first time that these neurons are susceptible to
BoNT/A treatment and that the assay was able to detect a
dose- and time-dependent inhibition of synaptic transmission to
picomolar (pM) concentrations of BoNT/A and the commercially
available pharmaceutical BOTOX R©.
MATERIALS AND METHODS
Mouse Embryonic Stem Cell Culture
Wild type mESCs (E14) (Hooper et al., 1987), a kind gift of
Marta Roccio (Inner ear research lab, Department of Clinical
Research, University of Bern, Switzerland) were maintained in
a 37◦C tissue culture incubator at 5% CO2 and differentiated
into mESN using previously described protocols with several
adaptations (Wichterle et al., 2002; Wichterle and Peljto, 2008;
Wu et al., 2011). Briefly, cells were maintained in tissue culture
flasks (TPP, Trasadingen, Switzerland) that had been coated for
30 min at 37◦C with 0.1% gelatine in ES medium consisting of
DMEM with Glutamax, 15% fetal bovine serum, embryonic stem
cell-qualified (GIBCO R©, Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with MEM non-essential amino
acids to a final concentration of 1 mM for all amino acids
(glycine, L-alanine, L-asparagine, L-aspartic acid, L-glutamic
acid, L-proline, L-serine), penicillin-streptomycin-glutamine to
a final concentration of 1000 Units/ml penicillin, 1000 µg/ml
streptomycin, and 0.292 mg/ml L-glutamine, 2-mercaptoethanol
(0.1 mM) as well as leukemia inhibitory factor to a final
concentration of 1000 Units/ml (Merck Millipore, Darmstadt,
Germany). Unless otherwise specified, all cell culture supplies
for embryonic stem cell maintenance, mESN differentiation
and mESN culture were obtained from Invitrogen (Paisley,
Scotland, UK). To elicit embryoid body (EB) formation and
induce differentiation of the mESCs, 1–2 × 106 cells were plated
on day 0 in a 10 cm tissue culture dish (TPP, Trasadingen,
Switzerland) and the medium was changed to a differentiation
medium termed DMNK+ consisting of a 1:1 mixture of
DMEM-F12/Glutamax and Neurobasal medium, supplemented
with penicillin-streptomycin-glutamine to a final concentration
of 1000 Units/ml penicillin, 1000 µg/ml streptomycin, and
0.292 mg/ml L-glutamine, 2-mercaptoethanol (0.1 mM), and 15%
KnockOutTM Serum Replacement. After 1 day in culture the
floating EBs were transferred into a 15 ml tube, centrifuged at low
speed (3 min; 35× g), resuspended in 10 ml of DMNK+ medium
and replated in a new 10 cm dish. On day 2 of differentiation,
EBs were supplemented with 1 µM retinoic acid to induce
neuralization. The next day, the medium was supplemented
with 1 µM of smoothened agonist (Merck Millipore, Darmstadt,
Germany). On day 7, EBs were dissociated using 2 ml of Accumax
(Merck Millipore, Darmstadt, Germany) for 10 min at room
temperature, diluted with 2 ml of DMNK+ medium and carefully
pipetted up and down 30 times using a 1000 µl pipette. Cells
were filtered through a 100 µm cell strainer (Becton Dickinson,
Bedford, MA, USA) to obtain a single cell suspension. This
step was performed three times to enrich the yield of single
cells. The suspension was then centrifuged (3 min; 35 × g)
and resuspended in 2 ml of DMNK+ medium supplemented
with recombinant rat glial cell-derived neurotrophic factor
Frontiers in Pharmacology | www.frontiersin.org 3 February 2017 | Volume 8 | Article 73
fphar-08-00073 February 22, 2017 Time: 16:49 # 4
Jenkinson et al. BoNT/A Detection Bioassay on MEAs
(10 ng/ml), recombinant human brain-derived neurotrophic
factor (10 ng/ml), and recombinant rat ciliary neurotrophic factor
(20 ng/ml) (all R&D Systems, Minneapolis, MN, USA). 2 × 105
cells/ml in 100µl of DMNK+medium supplemented with factors
were then plated on MEAs which were previously coated for
30 min at 37◦C with MatrigelTM (Corning, Corning, NY, USA)
diluted in 1:10 DMNK+ medium. The cells were then cultured
at 37◦C, 5% CO2 changing medium every 3 days. Exposure
to toxins and electrophysiological recordings were conducted
21 days (±2 days) after plating.
Multi-Electrode Arrays
Multi-electrode array slides (Qwane Biosciences, Lausanne,
Switzerland) composed of a glass substrate (700 µm thick,
21 mm × 21 mm) holding 68 black platinum electrodes with a
dimension of 40 µm × 40 µm, an inter-electrode distance of
200 µm holding an impedance of 10 k at 1 kHz and a 5 µm
thick SU-8 polymer layer for insulation were used. For culturing
of the cells, each MEA was placed into a 35 mm culture dish (TPP,
Trasadingen, Switzerland) holding 2 ml of DMNK+ medium.
Further, MEAs from MultiChannel Systems (MultiChannel
Systems GmbH, Reutlingen, Germany) composed of 60 Titanium
nitride electrodes with a diameter of 30 µm (59 recording
electrodes, 1 internal reference electrode), an inter-electrode
distance of 200 µm holding an impedance of <100 k and a
silicon nitride isolation were used. Further they hold a 6 mm high
glass ring around the electrodes allowing the addition of 1 ml of
DMNK+ medium.
Electrophysiological Recordings
Spontaneous neuronal activity was measured by detecting
extracellular voltage transients, induced by current flow through
membranes of neurons. MEAs were incorporated into a Plexiglas
chamber and mounted on an inverted microscope. To maintain
the pH at 7.4 the cultures were superfused with an extracellular
solution consisting of 145 mM NaCl, 4 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, 5 mM Hepes, 2 mM Na-pyruvate and
5 mM glucose, (all Sigma-Aldrich, St. Louis, MO, USA). The
68 electrodes were AC-coupled to an individual custom-made
amplifier and data were digitized at a rate of 6 kHz with 12
bit resolution and stored on a hard disk for oﬄine analysis
as described previously (Tscherter et al., 2001). To control the
A/D card (NI-DAQ-card, AT-MIO-64E-3, National Instruments,
Ennetbaden, Switzerland) a custom-made LabVIEW software
(National Instruments, Ennetbaden, Switzerland) was used. The
contribution of inhibitory neurons in our cultures was analyzed
under the treatment of a GABA A (10 µM gabazine) and
glycine (1 µM strychnine, both Sigma-Aldrich, St. Louis, MO,
USA) receptor antagonist and signals were recorded for 10 min
(n = 7, from three independent experiments) (Figure 3C). To
discriminate intrinsic neuronal activity and synaptic activity,
pharmacological identification of postsynaptic responses was
performed by application of a mixture of GABA A (10 µM
gabazine), glycine (1 µM strychnine), α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid/kainate (10 µM, CNQX) and
N-methyl-D-aspartate (50 µM APV) receptor antagonists (all
from Sigma–Aldrich, St. Louis, MO, USA) thus inhibiting all
synaptic transmission (Figures 3A,B). This step was conducted
at the end of every recording with each culture that showed
a remaining burst activity. Further, to distinguish background
noise from neuronal activity, every culture was treated as a final
step with 1 µM TTX (Alomone Labs, Jerusalem, Israel), a potent
voltage-gated sodium channel blocker, and recorded for 10 min.
The resulting activity was then set as a zero reference.
For long-term time-dependent analysis measurements a
commercially available MEA system (MultiChannel Systems
GmbH, Reutlingen, Germany) was used to measure the activity
21 days (±2 days) after plating the cultures. This setup
enabled to conduct measurements at different time points
without the risk of contamination. The signals from the MEAs
were amplified with a MEA2100 headstage and data were
digitized with a 60-channel A/D converter at a rate of 25 kHz
with 16 bit resolution. The measurement was controlled via
MC_Rack software (MultiChannel Systems GmbH, Reutlingen,
Germany) and the data were stored on a hard disk for
further analysis. The temperature was controlled with an
external heater unit (TC02, MultiChannel Systems GmbH,
Reutlingen, Germany) set to 37.6◦C. To eliminate evaporation
and contamination during the experiment the MEAs were
sealed with a semi-permeable membrane (ALA MEA-MEM,
ALA Scientific Instruments, Westbury, NY, USA), (Potter and
DeMarse, 2001). All recordings were conducted in DMNK+
medium. To discriminate intrinsic neuronal activity and synaptic
activity, pharmacological identification of postsynaptic responses
was performed as described above.
Analysis of Spontaneous Activity
Event detection and further analysis was performed oﬄine using
IGOR (WaveMetrics, Inc., Lake Oswego, OR, USA) as described
previously (Tscherter et al., 2001). The detected signals are
fast voltage transients (<4 ms) corresponding to single action
potentials or spikes in neuronal somata or axons (single unit
activity) and are represented by single time markers called
events. These are shown in event raster plots for each electrode
(Figure 2A). Usually, they appeared in clusters (multi-unit
activity) originating from closely timed action potentials of
several neurons seen by one or multiple electrodes. These multi-
unit activities were defined as burst (Figure 2C). Detected bursts
were subsequently defined oﬄine in IGOR by reaching a certain
threshold set individually for each culture with the beginning
being defined as the first event in a time window of at least 5 ms
and the burst end being the last event in a time window of at least
10 ms. Network activity plots (Figure 2B) show the total activity
of active electrodes within a sliding window of 10 ms shifted
by a 1 ms step. For calculation of the spike rate (spikes/s per
active electrode), spontaneously active electrodes were defined as
electrodes showing a minimum of 0.1 detected events per second.
Electrodes which detected fewer or 0 signals were not taken into
account.
BoNT Activity Assay
Due to the high toxicity of BoNTs, the handling requires
appropriate safety measures. Solubilized neurotoxins were
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handled in a level 2 biosafety cabined equipped with high-
efficiency particulate air filters. All consumables (e.g., pipette tips,
falcon tubes) and medium that were exposed to the toxin, as well
as the neurotoxin itself, were treated with 2 M NaOH (Sigma-
Aldrich, St. Louis, MO, USA) and incubated for at least 1 h
prior to discarding them in a separate container. These were
autoclaved and disposed in the biological waste containers within
the laboratory.
To assess the biologic activity of BoNT, 21 day (±2 days)
old cultures were exposed to either 1.66, 16.6, or 166 pM
of purified BoNT/A (A1 Hall Strain, Metabiologics, Madison,
WI, USA) diluted in PBS and incubated at 37◦C, 5% CO2 in
2 ml of DMNK+ medium. Cultures serving as control received
the equivalent volume of PBS containing no toxin. After 6 h,
cultures (treated and untreated) were washed twice with DMNK+
medium to remove all unbound toxin and neuronal activity
was measured during 10 min as described beforehand in the
electrophysiological recordings section. Serving as a negative
control, cultures were treated with 166 pM heat inactivated
BoNT/A (95◦C, 5 min) in PBS and incubated for 6 h at 37◦C,
5% CO2.
For long-term measurements 21 day (±2 days) old cultures
were exposed to either 1.66 pM of purified BoNT/A (A1 Hall
Strain, Metabiologics, Madison, WI, USA) or 33 Units/ml of
onabotulinumtoxin A (Botox R©, Allergan Inc., Dublin, Ireland)
diluted in PBS and incubated at 37◦C, 5% CO2 in 1 ml of
DMNK+ medium. Neuronal activity measured in all cultures
at the beginning of the experiment (0 h) served as baseline
activity. Upon treatment with the toxin, the cultures were
transferred after 6, 12, and 24 h from the incubator to
the MultiChannel Systems electrical recording system and
neuronal activity was measured. Before each recording the
cultures were allowed to settle for 5 min before spontaneous
neuronal activity was measured for 2 min. After completion
of the recordings the cultures were transferred back to the
incubator.
Immunocytochemistry
On day 7 of differentiation, EBs were dissociated as described
in Section “Mouse Embryonic Stem Cell Culture” and 2 × 105
cells/ml in 500 µl DMNK+ medium supplemented with growth
factors were plated on round cover glasses (Ø 12 mm,
HUBERLAB, Aesch, Switzerland) which were previously coated
for 30 min at 37◦C with MatrigelTM (Corning, Corning, NY,
USA) diluted 1:10 in DMNK+ medium. The cells were then
cultured at 37◦C, 5% CO2 for up to 21 days, changing medium
every 3 days. Following, cells were fixed in 4% paraformaldehyde
(Sigma-Aldrich, St. Louis, MO, USA) in PBS for 10 min, washed
three times with PBS and permeabilized with 0.1% Triton X-100
for 5 min (Sigma–Aldrich, St. Louis, MO, USA). Prior to staining,
cells were blocked for 2 h with 2% bovine serum albumin and
0.01% Triton X-100 (both Sigma–Aldrich, St. Louis, MO, USA).
Primary antibodies against β-III Tubulin (monoclonal mouse
anti β-III Tubulin, 1:500, R&D Systems, Minneapolis, MN, USA;
polyclonal rabbit anti β-III Tubulin, 1:500, Abcam, Cambridge,
UK), synaptic vesicle glycoprotein isoform A/B/C (monoclonal
mouse anti SV2, 1:100), GD1a ganglioside (monoclonal mouse
anti GD1a, 1:10), GT1b/2b ganglioside (monoclonal mouse
anti GT1b/2b, 1:10) (SV2 antibody developed by Buckley,
K.M., GD1a, and GT1b/2b antibodies developed by Schnaar,
R.L. obtained from the Developmental Studies Hybridoma
Bank, created by the NICHD of the NIH and maintained at
The University of Iowa, Department of Biology, Iowa City,
IA, USA), synaptic vesicle glycoprotein isoform C (polyclonal
rabbit anti SV2C, 1:500), SNAP-25 (monoclonal mouse anti
SNAP-25, 1:500), synapsin 1a/b (monoclonal mouse anti Syn1,
1:500), VGLUT 2 (monoclonal mouse anti VGLUT2, 1:500),
glutamate decarboxylase 1 (polyclonal rabbit anti GAD1,
1:500) (all Synaptic Systems, Goettingen, Germany), and
GFAP (polyclonal rabbit anti GFAP, 1:500) (Chemicon, Merck
Millipore, Darmstadt, Germany) were incubated over night at
4◦C in PBS with 2% bovine serum albumin and 0.01% Triton
X-100. The samples were washed three times with PBS and
secondary antibodies conjugated with Alexa 488, Alexa 555, and
Alexa 647 (all Invitrogen, Paisley, Scotland, UK) were incubated
the following day for 2 h at room temperature diluted 1:500 in
2% bovine serum albumin and 0.01% Triton X-100. Cells were
washed three times in PBS and mounted in FluoroshieldTM with
DAPI (Sigma–Aldrich, St. Louis, MO, USA) for nuclear staining.
Images were acquired with a Zeiss laser scanning confocal
microscope 710 using a Zeiss Plan-Apochromat 60x 1.4 NA
objective and a Nikon Eclipse Ti microscope using Nikon-Plan
Fluor 40x 1.0 NA and 63x 1.4 NA objectives.
Statistical Analysis
Graph Pad Prism software (version 6.0) was used for statistical
analyses. Differences between unpaired groups were evaluated
either using the two-tailed unpaired Mann–Whitney test or the
unpaired t-test. For comparison of paired groups a paired t-test
was conducted. A p-value < 0.05 (two-tailed) was considered as
statistically significant.
RESULTS
Neuronal Cultures Derived from mESCs
Form Synapses and Express the Proteins
Necessary for BoNT/A Intoxication
Three days after plating (data not shown) and throughout the
next 21 days, mESN expressed the post-mitotic neuronal marker
β-III Tubulin (Figures 1A–F, 2D). Immunocytochemistry
performed 21 days after plating the cells revealed, that a large
proportion of post-mitotic neurons expressed the VGLUT 2, a
known marker for glutamatergic neurons (Figure 1D). However,
only a minority of these cells were immunoreactive for GAD1,
a marker for GABAergic neurons (Figure 1E). Co-staining
with the universal pre-synaptic neuronal marker Syn1 proved
the presence of synaptic vesicles in axons of β-III Tubulin
positive cells (Figures 1D,E). In addition, neurons expressed
the polysialo gangliosides GD1a and GT1b/2b, both known to
mediate the initial anchorage of BoNT/A toward the presynaptic
membrane (Figure 1C). Furthermore, the expression of all
three pre-synaptic membrane receptor isoforms SV2 C/A/B
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FIGURE 1 | Representative immunocytochemistry demonstrating the expression of neuronal, synaptic, glutamatergic, GABAergic, and glial markers
in cultures 21 days after plating. Neuronal cultures were immunostained against β-III Tubulin (A–F); SNAP-25 (A); SV2 isoform A–C (A,B); polysialo gangliosides
GD1a and GT1b/2b (C) Syn1 (D,E); glutamatergic neurons (VGLUT2, D); GABAergic neurons (GAD1, E) and glial cells (GFAP, F). Shown also are DAPI nuclear
staining and the merged images. Scale bar is 10 µm (A–E), respectively, 25 µm for the bottom panel (F).
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FIGURE 2 | Electrophysiological characterization of mESN cultured on MEAs. (A, top) Raster plot of 62 single electrodes (represented by different colored
lines) showing high spontaneous neuronal activity of a culture 21 days after plating. The formation of bursts is based on spontaneous intrinsic activity and recurrent
excitation of the neuronal network through synaptic transmission. Events represent the neuronal activity recognized by the detector (see Materials and Methods). (A,
bottom) 10 s excerpt of the raster plot showing individual bursts. (B) Network activity plot. This plot visualizes the amount of activity in the whole neuronal culture
network during the time illustrated in the raster plot shown in (A). It shows the number of events detected from all active electrodes with a sliding window of 10 ms
shifted by a 1 ms step. Visible by the underlines are the beginning and ending of detected oscillating burst activities. (C) Raw data traces from three single MEA
electrodes. (D) Schematic representation of mESN cultured for 21 days on a MEA immunostained for β-III Tubulin (green), GFAP (red), and DAPI (blue). Highlighted in
white are the positions of each electrode. Scale bar is 20 µm.
(order expresses decreasing neurotoxin affinity) (Mahrhold
et al., 2006; Rummel, 2013) (Figures 1A,B), necessary for
docking and cytosolic uptake of BoNT/A as well as its target
protein SNAP-25 (Figure 1A) further confirmed that these cells
expressed the necessary components used by BoNT to inhibit
synaptic activity. After 21 days in culture, a high amount
of GFAP were observed, a proteins expressed by numerous
cell types of the central nervous system including astrocytes
(Figures 1F, 2D).
mESN Show High Spontaneous Synaptic
Activity
First single spikes, recorded from individual electrodes were
measured beginning 3 days after plating of the cells. At 6 days
after plating the cultures showed first synchronous spontaneous
activity over several electrodes simultaneously and reaching a
plateau at 21 days after plating, represented in the formation of
oscillating bursts (Figure 2A). The size of the bursts was random
and did not have any obvious periodicity and their occurrence
could not be predicted.
Next, we analyzed the contribution of the different
neurotransmitters to spontaneous postsynaptic events by
pharmacological interference. Inhibition of GABA A, glycine,
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/kainate
and N-methyl-D-aspartate receptors completely abolished the
remaining occurrence of bursts in every analyzed culture (n= 60)
(Figure 3A). However, asynchronous intrinsic activity was still
detectable, indicating that the neurons were still able to fire single
action potentials (Figure 3B). Inhibition of the GABA A and
glycine receptor by gabazine and strychnine, thus blocking the
effects of inhibitory neurons, led to a slight increase of the burst
rate (22.8 ± 5.11 vs. 23.4 ± 6.1 bursts/min; n = 7; from three
independent experiments), as well as mean spike rate (9.4 ± 3.9
vs. 11.5 ± 4.3 spikes/s per active electrode; p < 0.01; n = 7;
from three independent experiments) (Figures 3C,D). This
demonstrates the presence of inhibitory synaptic connections
involving GABA A and glycine receptors, in accordance with
our immunocytochemistry findings on the presence of a
small amount of GABAergic neurons (Figure 1D). Finally, all
spontaneous activity was eliminated by applying 1 µM TTX,
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FIGURE 3 | mESN cultured on MEAs for 21 days show functional glutamatergic and GABAergic synapses with network characteristics. (A) Event
raster plot and corresponding network activity plot of activity recorded following the addition of gabazine, strychnine, APV, and CNQX (highlighted by the blue bar).
This combination of receptor antagonists leads to an inhibition of synaptic transmission and thus preventing the formation of bursts as well as resulting in a dramatic
decrease of the average spike rate. (B) Note that under these conditions asynchronous intrinsic activity is still visible on several electrodes. Raw data traces are
shown for three electrodes (E 36, E 39, E 42) as well as for one electrode (E 36) after application of 1 µM TTX. (C) Network activity plot showing the activity prior
(top) and after treatment with 10 µM gabazine and 1 µM strychnine. (D) Note the slight increase in burst (left) as well as average spike rate (right). Data are given as
mean; paired t-test, two tailed; ∗∗P < 0.01; ns signifies as not significant.
indicating that the detected voltage transients originated from
neuronal activity (Figure 3B, bottom raw data trace).
Collectively, these data demonstrate the functional
development of glutamatergic and GABAergic synapses
within our mESC-derived neuronal network.
mESN Cultured on MEAs Can Sensitively
Detect the Biological Activity of BoNT/A
in a Dose- and Time-Dependent Manner
Next, we evaluated the effect of BoNT/A exposure on the average
network activity, defined by changes in burst and spike rates, in
a dose- and time-dependent fashion. Exposure to BoNT/A for
6 h resulted in a significant decrease of the burst rate for toxin
concentrations of 166 pM (43.9 ± 24.9%; p < 0.0005; n = 6)
and 16.6 pM (66.7 ± 42.5%; p < 0.005; n = 16) compared
to untreated cultures (100 ± 19.7%; n = 27) (Figure 4A).
A significant decrease in the mean spike rate was observed for
toxin concentrations of 166 pM (28.7± 20.0%; p < 0.005; n= 6)
and 16.6 pM (78.0 ± 70.9%; p < 0.05; n = 16) compared to
untreated cultures (100 ± 31.9%; n = 27) (Figure 4B). However,
no significant decrease in burst rate (108.7 ± 25.2%; p = 0.25;
n= 9) (Figure 4A) and mean spike rate (91.5± 67.3%; p= 0.38;
n = 9) (Figure 4B) was observed upon treatment with 1.66 pM
BoNT/A for 6 h.
To exclude that the observed effect of the toxin on neurons
may be due to protein properties unrelated to its biological
activity, cultures (n = 5) were treated with 166 pM of heat
inactivated (5 min, 95◦C) BoNT/A for 6 h. It has previously been
shown, that heating BoNT/A for 15 s at 72◦C was sufficient to
reduce its toxic activity by more than 99.99% (Weingart et al.,
2010). Compared to a control (untreated group, n= 3), we could
not detect any significant difference in the burst or spike rate after
6 h (Figure 4C) indicating that the decrease of activity was indeed
caused by the specific biological activity of BoNT/A.
It has been shown, that BoNT/A leads to a time-dependent
increase of SNAP-25 cleavage as well as decrease in the network
activity (Pellett et al., 2011; Beske et al., 2015). We therefore
examined whether longer exposure periods with 1.66 pM
BoNT/A would lead to a decrease of the network activity. In
control cultures exposed to PBS only, there was no significant
changes over time in either the burst or mean spike rate
(Figures 5A,C). After 12 h of incubation with 1.66 pM BoNT/A
the overall burst rate of the neuronal cultures was reduced by
62.9% (37.1 ± 48.0%; n = 4) and the mean spike rate was
reduced by 36.6% (63.4 ± 36.9%; n = 4) comparing to the
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FIGURE 4 | mESN grown on MEAs are susceptible to intoxication by BoNT/A in a dose-dependent manner. Treatment and incubation for 6 h with 16.6
and 166 pM BoNT/A resulted in a significant decrease of the burst rate and the mean spike rate. Cultures receiving no toxin served as control. (A) Reduction of the
burst rate compared to the control group. (B) Reduction of the mean spike rate compared to the control group. Mann–Whitney two tailed test; ∗P < 0.05;
∗∗P < 0.01; ∗∗∗P < 0.001; ns signifies as not significant. (C) Treatment and incubation with 166 pM heat inactivated BoNT/A showed no significant difference in
burst (left) as well as average spike rate (right). Paired t-test, two tailed; ns signifies as not significant.
baseline activity (highlighted by the dotted line) determined
prior to treatment (Figure 5C). At 24 h post treatment with
1.66 pM BoNT/A a complete loss of synaptical driven activity was
observed resulting in the complete absence of burst formation
when compared to the baseline activity (Figure 5B, right panel
and Figure 5C, left panel). Further, the average spike rate was
reduced by 80.5% (19.5 ± 17.4%; n = 4) when compared to the
baseline activity. Solely the asynchronous intrinsic activity was
detectable (Figure 5B, right panel and Figure 5C, right panel).
By comparing the untreated control group receiving only PBS
toward BoNT/A treated cultures 24 h post treatment, significant
decreases of both the burst rate (105.0 ± 10.1%; n = 3) vs.
(0.0 ± 0.0%; p < 0.0001; n = 4) (Figure 5C, left panel) and
the mean spike rate (103.6 ± 9.5%; n = 3) vs. (19.5 ± 17.4%;
p < 0.001; n= 4) (Figure 5C, right panel) were observed.
Pharmaceutical preparations with onabotulinumtoxin A
(Botox R©, Botox Cosmetics R©, Vistabel R©, Vistabex R©) contain the
150 kDa holotoxin BoNT/A and several non-toxic clostridial
accessory proteins which are covalently bonded to the 150 kDa
holotoxin forming a BoNT/A complex. We therefore assessed,
if BoNT/A complex interferes with the sensitivity or kinetics of
the described assay. Upon treatment with 33 Units/ml of Botox R©,
corresponding to approximately 1.66 pM of BoNT/A based on
its reported specific activity, and incubation for 24 h a complete
loss of synaptical driven activity was observed resulting in the
complete absence of burst formation when compared to the
baseline activity (Figure 5C, left panel). Comparing the average
spike rate 24 h post treatment with an untreated control group, a
significant decrease in activity was observed (103.6± 9.5%; n= 3)
vs. (19.2± 3.2%; p < 0.001; n= 3) (Figure 5C, right panel).
Overall these data indicate, that mESN grown on MEAs can
detect the biological activity of BoNT/A holotoxin in a time- and
dose-dependent manner resulting in a decrease of synaptically
mediated neuronal activity. Further, no impairment regarding
kinetics or sensitivity was observed using BoNT/A complex that
is contained in the pharmaceutical preparation Botox R©.
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FIGURE 5 | Time-dependent reduction of synaptic transmission upon addition of BoNT/A holotoxin and complex. (A) Raster plot and corresponding
network activity plot showing spontaneous burst activity of a 21-day-old control culture prior (left) and 24 h after receiving 10 µl of PBS (right). (B) Upon treatment
and incubation with 1.66 pM BoNT/A for 24 h a complete loss of synchronous burst activity is visible (right). Seen on the left is the same culture prior to addition of
the toxin serving as the base activity at 0 h (left). (C) Decrease of the burst rate (left) and the mean spike rate (right) upon treatment and incubation with 1.66 pM
BoNT/A or 33 Units/ml Botox R© at the indicated time points. Each culture was normalized toward its base activity measured at time point 0 h (highlighted by the
dotted line). The reduction of the activity was then compared toward untreated cultures serving as a control. Unpaired t-test, two tailed; ∗∗∗P < 0.001;
∗∗∗∗P < 0.0001; ns signifies as not significant.
DISCUSSION
The in vivo MBA was introduced in the 1920s and is still
considered as the gold standard method for the detection of
BoNTs. It has a high sensitivity, with detection limits at 20 pg/ml
(0.13 pM BoNT/A), can detect all steps of BoNT intoxication and
is able to detect all functionally active BoNT serotypes (Lindstrom
and Korkeala, 2006; Dorner et al., 2013). However, due to
considerable ethical concerns and a number of disadvantages
there is a high demand for the replacement of the MBA. Here,
neuronal cell-based assays can provide an alternative method for
the detection of BoNT activity in pharmaceutical preparations.
BoNT/A leads to cleavage of the essential SNARE protein SNAP-
25 thus leading to the inhibition of neurotransmitter release from
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the pre-synaptic compartment in peripheral neurons (Rossetto
et al., 2014). Therefore, treatment of in vitro cultures should
lead in theory to a reduction or elimination of synaptical driven
network responses.
In this study, we demonstrated that mESN grown on MEAs
can serve as a physiologically relevant, cell-based model for
the detection of BoNT/A holotoxin and complex. We showed
that mESN form functional networks, express the receptors
and proteins necessary for BoNT/A intoxication and show
high spontaneous activity resulting in the formation of bursts
(Figure 2A). Further, upon treatment for 24 h with 1.66 pM
BoNT/A or 33 Units/ml Botox R© a complete silencing of synaptic
transmission was observed and this decrease in activity is a
function of concentration and time (Figures 4A,B, 5C). This
observation is consistent with other published data where the
incubation of neuronal cultures with 20 pM of BoNT/A for
20 h led to a cleavage of 95% of total cellular SNAP-25 leading
to an impairment of synaptic activity (McNutt et al., 2011;
Beske et al., 2015). In addition, the persistence of asynchronous
intrinsic activity after BoNT/A treatment indicates that the effect
is not attributable to overall cytotoxicity (Figure 5B, right panel).
The observed sensitivity towards BoNT/A is in agreement with
other published studies which showed sensitivity in the range
of 0.03–500 pM. The majority of these studies, however, rely
on the detection of SNARE cleavage in cell lysates by Western
blot (McNutt et al., 2011; Pellett et al., 2011; Fernandez-Salas
et al., 2012; Whitemarsh et al., 2012), or by direct/ capture ELISA
(Nuss et al., 2010). Although high sensitivity can be reached by
cleavage assays, most approaches require cell lysis and therefore
exclude longitudinal data sampling. Kiris et al. (2011) showed in
a previous study a possible high-throughput method by detecting
SNARE cleavage upon BoNT/A treatment in live cells by
quantitative immunofluorescence allowing for continuous data
sampling. However, only concentrations down to 25 pM BoNT/A
were tested (Kiris et al., 2011). An interesting approach was
conducted by Dong et al. (2004) where a SNARE-FRET construct
was transiently expressed in PC12 cells which allowed the study
of toxin substrate cleavage in situ. Though they could successfully
detect BoNT/A activity, the assay lacked the required sensitivity
(50 nM) and incubation times of 96 h were necessary (Dong
et al., 2004). On the contrary, using electrophysiological methods
and observing the inhibition of synaptic transmission in response
to BoNT poses a non-invasive and sensitive method allowing
for continuous recording. Two previous studies reported the
use of primary cortical and spinal neurons grown on MEAs
as a detection model for BoNT/A. They showed a sensitivity
toward BoNT/A of 13 pM after 24 h (Pancrazio et al., 2014)
and 1.3 pM after 48 h (Scarlatos et al., 2008). For both studies
either E16-17 mice embryos (Pancrazio et al., 2014) or E17-18
rat embryos (Scarlatos et al., 2008) were sacrificed and primary
neurons harvested. By using whole-cell patch-clamp recordings
on mESN a recently published study showed a calculated half
maximal inhibitory concentration value of 55 fM for BoNT/A
(Beske et al., 2016). Although they were able to show sensitivity
equal to the MBA, patch-clamp electrophysiology is a low-
throughput method requiring specialized techniques and trained
staff. In contrast, commercially available MEA systems allow for
a high-throughput screening. This has been shown in different
studies assessing drug effects on cardiomyocytes derived from
human embryonic stem cells or human-induced pluripotent stem
cells (Mandenius and Meyer, 2013; Clements and Thomas, 2014;
Gilchrist et al., 2015; Clements, 2016). In addition, they offer
tailored software packages that allow non-trained staff to operate
the system. However, differentiation of mESCs toward neurons
still needs trained staff and during the first week of differentiation
hands-on time is required. Here, the usage of commercially
available cryopreserved human induced pluripotent stem cell-
derived neurons could reduce hands-on time to a minimum
and only basic knowledge of tissue culture techniques is
required. These commercially available cells undergo strict
quality controls, thus enabling reproducible neuronal cultures.
Further, it has been shown that human induced pluripotent stem
cell-derived neurons are highly sensitive to BoNT/A with a half
maximal effective concentration of around 0.3 mouse LD50 Units
(Whitemarsh et al., 2012). A main drawback, however, is the low
sensitivity toward BoNT/B being around 16 mouse LD50 Units. It
is believed that this is due to a single point mutation in the human
neuronal protein receptor synaptotagmin II which decreases the
affinity toward BoNT/B (Strotmeier et al., 2012; Rummel, 2013).
Therefore, one must considerer species specificity when detecting
different BoNT serotypes.
The formation of spontaneous activity observed in our
cultures is a common characteristic during development of
neuronal networks both in vivo and in vitro and our data is
comparable to other studies showing over time the formation
of spontaneous burst activity in primary networks in vitro
(Maeda et al., 1995; van Pelt et al., 2004; Czarnecki et al.,
2012) and mESC-derived networks in vitro (Ban et al., 2007).
These bursts are based on spontaneous intrinsic activity and
recurrent excitation of the neuronal network through synaptic
transmission (Darbon et al., 2002; Yvon et al., 2007). Our cultures
are composed of a heterogeneous mixture of excitatory and
inhibitory neurons which is comparable to previous studies that
show the presence of GABAergic and glutamatergic neurons in
mESC-derived cultures (Ban et al., 2007; Beske et al., 2015) or
cortical cultures (Czarnecki et al., 2012). Clostridial toxins affect
not only cholinergic peripheral synapses but also possess the
ability to affect all kind of synapses (Verderio et al., 2007; Akaike
et al., 2010; Beske et al., 2015). Interestingly, it has been observed
in vitro that spinal cord synapses as well as synapses of mESN
differ in their susceptibility toward BoNTs where GABAergic
neurons show a higher sensitivity than glutamatergic neurons
(Akaike et al., 2010; Beske et al., 2015). It is postulated that this
effect is due to the higher firing rate of inhibitory neurons leading
to a higher rate of synaptic vesicle endocytosis and thus causing a
more rapid uptake of the toxin (Beske et al., 2015). These synapse-
specific differences in latency would therefore lead to a biphasic
response where initially an increase of network activity would
be observed. This effect has been reported by different studies
in vitro where primary cortical neurons (Scarlatos et al., 2008),
spinal cord neurons (Pancrazio et al., 2014) or mESN (Beske et al.,
2015) show a synapse subtype specific latency toward intoxication
leading to an initial increase of network activity. In the present
study, upon treatment with BoNT/A we did not observe an initial
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increase of network activity. Previous studies (Pancrazio et al.,
2014; Beske et al., 2015) showed that this initial increase occurs
as early as 30 – 60 min after BoNT/A addition and is therefore
not detectable in the present experimental setup. The treatment
with GABA A and glycine receptor antagonists, thus isolating the
effects of inhibitory neurons, showed only a minor increase in the
burst as well in the total network activity (Figure 3D). Comparing
these results with our immunocytochemistry characterization
and previously published studies, this data suggests that only a
small population of neurons show a GABAergic phenotype. To
increase the sensitivity of our in vitro bioassay and achieve a
shorter readout time one could consider using a differentiation
protocol yielding a higher GABAergic neuronal population
(Westmoreland et al., 2001; Chatzi et al., 2009). In addition,
the high amount of glial cells in our cultures reflects the
prolonged period of in vitro differentiation which is required for
a network formation (Figure 1F). An increased number of GFAP
positive cells over time is concordant with in vivo developmental
progression as well as with neural stem cell differentiation
studies in vitro (Sauvageot and Stiles, 2002; Abranches et al.,
2009).
In summary, we have shown that electrophysiological
detection of network activity provides a physiological relevant
readout of BoNT/A intoxication. Further, we could show that
BoNT/A complex and the presence of pharmaceutical excipients
do not alter the sensitivity or kinetics of the described assay.
Unlike most cell-based assays which are customized for specific
BoNT serotypes, mESN can be used for detection of a range of
BoNT serotypes (Beske et al., 2016). Further, culturing mESN
on MEAs allows for a non-invasive and continuous monitoring
of synaptic transmission reflected by burst activity and unlike
primary cultures no animals are required for the assay. In
addition, the problem of scalability regarding primary neuron
harvest is not an issue and the used MEA setup allows for a
prospective high-throughput screening. However, a limitation at
the time being is the restricted sensitivity to concentrations down
to 1.66 pM. Future studies will be necessary to better understand
the effects of BoNTs on neuronal networks and increase the
sensitivity. Once these issues are addressed, the present system
holds the potential to reduce animal use for BoNT detection and
activity determination.
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